A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

NCT03114865 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
B-cell Non Hodgkin Lymphoma
Pre B-Cell Acute Lymphoblastic Leukaemia

Interventions

DRUG: Blinatumomab 9ug
DRUG: Blinatumomab 28 ug
DRUG: Blinatumomab
DRUG: Dexamethasone

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]